LNZ101 (aceclidine + brimonidine)
Presbyopia
Phase 3Active (CLARITY-1 & CLARITY-2 trials)
Key Facts
About LENZ Therapeutics
LENZ Therapeutics is dedicated to addressing significant unmet needs in ophthalmology, starting with presbyopia, a condition affecting over 1.8 billion people globally. The company's lead product candidates, LNZ100 (aceclidine) and LNZ101 (aceclidine + brimonidine), are designed as once-daily eye drops that temporarily constrict the pupil to create a pinhole effect, thereby improving near vision. With positive Phase 2 data and pivotal Phase 3 trials underway, LENZ aims to bring the first FDA-approved pharmacological treatment for presbyopia to market. The company went public via a merger with Graphite Bio in March 2024 to fund its late-stage development.
View full company profileTherapeutic Areas
Other Presbyopia Drugs
| Drug | Company | Phase |
|---|---|---|
| ANX007 | Annexon | Preclinical |
| LNZ100 (aceclidine) | LENZ Therapeutics | Phase 3 |